Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M006628200 on August 30, 2000

J. Biol. Chem., Vol. 275, Issue 46, 36181-36188, November 17, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/46/36181    most recent
M006628200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edwards, T. K.
Right arrow Articles by Rubin, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edwards, T. K.
Right arrow Articles by Rubin, E. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Role for Nucleolin/Nsr1 in the Cellular Localization of Topoisomerase I*

Troy K. EdwardsDagger, Ahamed SaleemDagger, Jeffrey A. Shaman, Tracey Dennis, Claudia Gerigk, Elder Oliveros, Marc R. Gartenberg, and Eric H. Rubin§

From the Departments of Medicine/Pharmacology, Cancer Institute of New Jersey/Robert Wood Johnson Medical School-University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901

Received for publication, July 25, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Nucleolin functions in ribosome biogenesis and contains an acidic N terminus that binds nuclear localization sequences. In previous work we showed that human nucleolin associates with the N-terminal region of human topoisomerase I (Top1). We have now mapped the topoisomerase I interaction domain of nucleolin to the N-terminal 225 amino acids. We also show that the Saccharomyces cerevisiae nucleolin ortholog, Nsr1p, physically interacts with yeast topoisomerase I, yTop1p. Studies of isogenic NSR1+ and Delta nsr1 strains indicate that NSR1 is important in determining the cellular localization of yTop1p. Moreover, deletion of NSR1 reduces sensitivity to camptothecin, an antineoplastic topoisomerase I inhibitor. By contrast, Delta nsr1 cells are hypersensitive to the topoisomerase II-targeting drug amsacrine. These findings indicate that nucleolin/Nsr1 is involved in the cellular localization of Top1 and that this localization may be important in determining sensitivity to drugs that target topoisomerases.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Human Top11 is a nuclear protein involved in the regulation of DNA structure and is the target of an important new class of antineoplastic drugs, the camptothecins (1, 2). Studies in yeast provide convincing evidence that Top1 is the sole cellular target for camptothecins, with this knowledge facilitating attempts to understand the mechanisms by which the drug destroys cells (3-5). Top1 is a monomeric protein that relaxes supercoiled DNA by creating a transient single-strand nick, with this nick involving the covalent attachment of Top1 to the DNA phosphate backbone via a phosphotyrosine bond. Recent structural studies of Top1 and the Top1-DNA covalent complex led to molecular models of the mechanism by which camptothecins inhibit the catalytic activity of Top1 (6-8). Nevertheless, formation of CPT-Top1-DNA ternary complexes is insufficient to explain the cytotoxic effects of CPT (9-11). Current models invoke interactions between ternary complexes and replication or transcriptional machinery as being important in conversion of ternary complexes to lethal forms of DNA damage (12, 13). However, it is not known whether physical interactions between Top1 and other proteins (including proteins involved in replication or transcription) are important in the cytotoxic effects of CPT. Recently, an interaction between Top1 and the SV40 T antigen helicase was shown to modulate formation of Top1-CPT-DNA ternary complexes, suggesting that similar interactions between Top1 and cellular helicases may mediate the cytotoxicity of CPT (14). In addition, Top1 rapidly redistributes from the nucleolus to the nucleus or cytoplasm and is degraded after cellular exposure to CPT (15-19). These alterations may confer transient cellular resistance to CPT and could be mediated by interactions between Top1 and other proteins.

Top1 is known to physically interact with the following proteins: HMG17 (20), casein kinase II (21), RNA polymerase I (22), nucleolin (23), SV40 T antigen (24, 25), p53 (26, 27), the TATA-binding protein (28), the splicing factors SF2/ASF (29) and PSF/p54nrb (30), and a novel RING finger protein named topors (31). Recently, two yTop1p-binding proteins were also identified (Tof1p and Tof2p) (32). Although relatively little is known regarding either protein, a Tof2p paralog, Net1p, is required for the proper nucleolar localization of Sir2 and Cdc14 (33, 34).

Since helicases may generate supercoiling problems that are resolved by topoisomerases, a need for physical interactions between these two enzyme classes is easily understood. Indeed, binding of Top1 by T antigen is one of several examples of a physical interaction between a helicase and a topoisomerase (35). The biochemical relevance of interactions between Top1 and other proteins is less clear. With regard to the nucleolin-Top1 interaction, there are three major domains in nucleolin: an acidic N terminus that contains multiple putative phosphorylation sites, a middle region containing four RNA-binding domains (RBDs), and a C-terminal glycine-arginine-rich (GAR) domain. In addition to binding RNA and DNA (36, 37), nucleolin was reported to be a helicase (38) and to function in nucleocytoplasmic transport by binding nuclear localization sequences (NLSs) (39, 40). Several lines of evidence indicate that both nucleolin and Top1 are involved in rRNA synthesis and processing (41-49). To gain insight into the cellular role of the nucleolin-Top1 interaction, we studied both a recombinant form of nucleolin and the Saccharomyces cerevisiae nucleolin ortholog NSR1. We find that the N terminus of nucleolin is necessary and sufficient for Top1 binding. Moreover, our results indicate that NSR1 is involved in the cellular localization of yTop1p and that loss of NSR1 alters cellular sensitivity to topoisomerase-targeting drugs but not to DNA damaging agents in general.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Strains and Plasmids-- S. cerevisiae strains used in this work are listed in Table I. MRG13 is a MATalpha derivative of MRG5 (50). TE25 was generated by transformation of FW251 with plasmid pICS16, which is designed to replace a 0.35-kilobase region in the NSR1 coding sequence with the URA3 gene (51). Disruption of NSR1 was confirmed by PCR using primers that flank the 5' integration site (data not shown), as well as by immunoblotting using an Nsr1p antibody. An identical strategy was used to disrupt NSR1 in strains MRG13 and JN284, yielding TE13 and TE284, respectively. Immunoblotting was used to confirm loss of Nsr1p in TE13 and TE284.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Yeast strains

Yeast expression plasmids encoding nucleolin deletion fragments linked to GST were constructed using PCR (primers for this, and subsequently described PCRs are available upon request) with the pKG-Nuc plasmid (25) as a template. PCR products were ligated into the pKG vector (54) using the SmaI and HindIII sites in this vector. The resulting plasmids were named according to the encoded nucleolin residues and include pKG-Nuc1-323, pKG-Nuc323-707, pKG-Nuc1-225, pKG-Nuc224-323, pKG-Nuc1-125, and pKG-Nuc125-225. Regions of these vectors corresponding to 5'-cloning sites were sequenced to confirm that the proper recombinants had been obtained.

Plasmid pKG-Nsr1 expresses Nsr1p linked to the C terminus of GST and was constructed using SmaI/HindIII restriction sites and PCR with pYCB5 (51) as a source for the NSR1 coding sequence.

Plasmid pYX-GFP expresses GFP in yeast under the control of the GAL1-10 promoter and was constructed using PCR with the pEGFP-C1 vector (CLONTECH) as a source for GFP coding sequence. The GFP PCR product was ligated into the BamHI and HindIII sites of the pYX133 vector (Ingenius Co., Oxford, United Kingdom). Similar strategies were used to generate pYX-GFP-yTop1 and pYX-GFP-Nop1, which express GFP-yTop1p and GFP-Nop1p fusion proteins, respectively. For the former vector, pYCpScTOP1 (provided by Mary-Ann Bjornsti) was used as template to obtain a PCR product containing the S. cerevisiae TOP1 coding sequence. The HindIII and XhoI sites in pYX-GFP were used to place TOP1 downstream from the GFP coding sequence in this vector. The same strategy and restriction sites were used to generate pYX-GFP-Nop1. The source of NOP1 coding sequence was S. cerevisiae genomic DNA from strain W303-1A (55). Expression of an appropriately migrating GFP fusion protein in cells transformed with the pYX-GFP-yTop1 or pYX-GFP-Nop1 vectors was confirmed by SDS-PAGE and immunoblotting using a GFP antibody (data not shown).

Antibodies and Drugs-- Monoclonal antibodies were generously provided by the listed individuals for the following proteins: nucleolin, Ning-Hsing Yeh (56); Nsr1p, M. Snyder and C. Copeland2; human Top1, Y. C. Cheng (57). A polyclonal yTop1p antibody was obtained from Mary-Ann Bjornsti. Monoclonal GFP and actin antibodies were obtained from Roche Molecular Biochemicals and Amersham Pharmacia Biotech, respectively, and a polyclonal GST antibody was obtained from Amersham Pharmacia Biotech.

Camptothecin lactone (CPT), methyl methane sulfonate, m-AMSA, and 1,10-phenanthroline were obtained from Sigma. Stock solutions were prepared for CPT at 5 mg/ml in Me2SO, for m-AMSA at 10 mg/ml in Me2SO, and for phenanthroline at 100 mg/ml in ethanol. Bleomycin sulfate was obtained as a 3 units/ml stock from Bristol-Myers Squibb Co.

GST Pull-down Assays-- Expression and purification of full-length nucleolin and nucleolin fragments using the pKG-Nuc plasmid and derivatives were performed as described previously (25). HeLa cell nuclear extracts were prepared by lysing cells in 0.35% Triton X-100 followed by extraction with 0.5 M NaCl as described (58). Pull-down assays using HeLa nuclear extracts and 10 µl of glutathione beads (Amersham Pharmacia Biotech) loaded with approximately 4 µg of purified GST, GST-nucleolin, or GST-nucleolin deletion fragments were performed in 1 ml of binding buffer (phosphate-buffered saline containing 0.2% Tween 20, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 0.5 µg/ml leupeptin, and 1 µg/ml pepstatin) with approximately 20 µg of nuclear extract. After a 1-h incubation at 4 °C, the beads were washed four times with binding buffer. Proteins remaining bound to the beads were examined by SDS-PAGE and immunoblotting using Top1 and GST antibodies.

For pull-down assays using yeast extracts, cells were grown at 30 °C in appropriate media to an A600 of 0.7-0.9, then pelleted and resuspended in 3 volumes of ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1 mM DTT, and 1% sodium deoxycholate) with freshly added protease inhibitors (1 mM EDTA, 1 mM PMSF, 0.5 µg/ml leupeptin, and 1 µg/ml pepstatin). The suspension was vortexed with acid-washed glass beads for 10 min at 4 °C and the resultant lysate cleared by centrifugation at 1,000 × g for 5 min. The supernatant was removed and cleared of remaining precipitate by centrifugation at 14,000 × g for 5 min, followed by incubation with 20 µl of glutathione beads for 2 h at 4 °C. After washing the beads twice with 1 ml of RIPA buffer, bound proteins were analyzed by boiling the beads in loading dye, followed by SDS-PAGE and immunoblotting.

Fluorescence Microscopy-- Yeast transformed with pYX-GFP, pYX-GFP-yTop1, or pYX-GFP-Nop1 were first grown to an A600 of 0.8 in media containing 2% raffinose but lacking tryptophan. Expression of GFP fusion proteins was induced by the addition of galactose to a 2% concentration, followed by an additional 2-h incubation. 4',6-Diamidino-2-phenylindole (DAPI) staining was performed by washing and resuspending cells in water, followed by addition of DAPI to a 0.1 µg/ml concentration. After a 10-min incubation at room temperature, the cells were washed once with 50% ethanol and once with water, then resuspended in water. Cells were co-imaged by phase contrast and fluorescent microscopy using a Ziess Axioskop fluorescent microscope equipped with a DC-330T, high resolution CCD camera (Dage MTI, Michigan City, IN). Concurrent GFP and DAPI fluorescence imaging was accomplished using Endow GFP bandpass emission (excitation and emission wavelengths of 430-510 and 475-575 nm, respectively) and DAPI (excitation and emission wavelengths of 320-400 and 410-450 nm, respectively) filter sets (Chroma Technology, Brattleboro, VT). Images were captured digitally using Scion Image software (Scion Corp., Frederick, MD) and cropped using Adobe Photoshop.

Preparation of Whole Cell, Nuclear, and Cytoplasmic Yeast Lysates-- Yeast whole cell lysates were prepared as described above for pull-down assays. For fractionation of nuclear and cytoplasmic proteins, yeast cell pellets were resuspended in spheroplast buffer (50 mM Tris-HCl, pH 7.5, 3 mM DTT, 10 mM MgCl2, and 1 M sorbitol) and incubated at room temperature for 15 min. The cells were then incubated with spheroplast buffer with 2 mg/ml Zymolase 100T (Seikagaku, Tokyo) for 40 min at 37 °C. The resulting spheroplasts were lysed in the following buffer: 18% Ficoll-400, 10 mM Tris-HCl, pH 7.5, 20 mM KCl, 5 mM MgCl2, 3 mM DTT, 1 mM EDTA, 1 mM PMSF, 0.5 mg/ml leupeptin, and 1 mg/ml pepstatin. The lysate was centrifuged at 3,000 × g to pellet unlysed cells and spheroplasts. Nuclei were then pelleted by centrifugation at 20,000 × g for 20 min at 4 °C. The supernatant, containing cytoplasmic lysate, was dialyzed against phosphate-buffered saline, then concentrated using a Centricon 30 concentrator (Amicon, Beverly, MA). Nuclei were lysed by boiling in SDS-PAGE loading dye.

Yeast Growth and Drug Sensitivity Assays-- For growth rate assays, yeast were grown overnight in YPD medium in a shaking 30 °C water bath to stationary phase. After dilution in fresh media to an A600 of approximately 0.03, subsequent growth at 30 °C was monitored by removal of aliquots and measurement of A600. If A600 measurements were greater than 0.8, the aliquots were diluted in media 2-fold to ensure that the A600 value remained linear with respect to cell number, with the linear range established by independent experiments.

Least squares regression analysis was used to quantify the slopes of the exponential phase of growth for each strain, ascertained by plotting log10A600 as a function of time. Differences in slopes among the strains were examined using a two-sample t test. A p value of <0.05 was considered significant.

For drug sensitivity assays, cells were grown overnight and adjusted to an A600 of 2.0 using fresh YPD media. Aliquots of 4 µl obtained from serial 10-fold dilutions were spotted onto YPD plates containing various drug concentrations, with the plates then incubated at 30 °C for 2 days. Plates containing CPT were prepared with 25 mM HEPES, pH 7.2, and 0.125% Me2SO as described previously (59). In other experiments, equal numbers of cells (ranging from 200 to 400) were dispersed on YPD plates containing either no drug or various concentrations of drug. After incubation at 30 °C for 2 days, colonies greater than 1 mm in diameter were counted.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The N Terminus of Nucleolin Is Necessary and Sufficient for Top1 Binding-- To identify regions of nucleolin involved in Top1 binding, we generated a recombinant protein consisting of nucleolin fused to the C terminus of GST. Since we were unable to express a fusion protein containing the full-length nucleolin protein in bacteria, we used a galactose-inducible yeast expression system (54). The GST-nucleolin fusion protein was purified from yeast extracts using glutathione affinity chromatography and analyzed by SDS-PAGE and immunoblotting. Purified preparations of GST-nucleolin contained a predominant Mr 126 band, which is the expected migration of a GST-nucleolin fusion protein (Fig. 1A). This Mr 126 protein was recognized by both nucleolin and GST antibodies (Fig. 1B and data not shown). To determine whether the recombinant nucleolin binds Top1, beads loaded with either purified GST-nucleolin or GST alone were incubated with HeLa cell nuclear extracts in a phosphate-buffered saline-based buffer. Beads containing GST-nucleolin, but not GST alone, bound Top1 in HeLa nuclear extracts (Fig. 1C). Taken together with our previous results using purified mammalian nucleolin (23), these data indicate that both purified and recombinant nucleolin bind Top1 in vitro.


View larger version (5K):
[in this window]
[in a new window]
  		Fig. 1.   Recombinant nucleolin binds Top1. A, lysates from yeast cells expressing GST or GST-nucleolin were purified using glutathione beads, followed by SDS-PAGE and silver staining. Each lane represents protein removed from 10 µl of purified beads by boiling in loading dye. B, proteins removed from 10 µl of purified beads were analyzed by SDS-PAGE and immunoblotting using a nucleolin antibody. 2 µg of HeLa nuclear lysate were loaded as a control. C, GST pull-down assays were performed using 20 µg of HeLa nuclear lysate and 10 µl of beads containing ~4 µg of GST or GST-nucleolin. Bound proteins were analyzed by SDS-PAGE and immunoblotting using a Top1 antibody. The lane labeled nuclear lysate represents 2 µg of nuclear lysate loaded directly onto the gel.

Next, we investigated Top1 binding by a series of nucleolin deletion fragments. We expressed and purified nucleolin fragments containing the acidic N-terminal region () or portions thereof (, ), or the remainder of the protein, consisting of the four RBD motifs and the GAR C-terminal domain (323-707; Fig. 2A). In each case, the purified preparation contained a band of the expected mobility that was reactive with a GST antibody (Fig. 2). In some preparations lower molecular weight bands that were reactive with the GST antibody were also detected and presumably represent degradation products (Fig. 2, A and B). In pull-down assays using HeLa nuclear extracts and GST-nucleolin fragments, an N-terminal nucleolin fragment containing residues 1-225 was identified as being necessary and sufficient for binding of Top1 (Fig. 2B). Immunoblotting with a GST antibody indicated that these results could not be explained by the presence of different quantities of GST-nucleolin fragments (Fig. 2B). Additional experiments indicated that two discrete fragments within the nucleolin N-terminal region, 1-125 and 125-225, were both capable of binding Top1, although more Top1 was bound by the 125-225 fragment than by the 1-125 fragment (Fig. 2C). Immunoblotting with a GST antibody indicated that this phenomenon was not due to the presence a greater quantity of the 125-225 fragment relative to the 1-125 fragment (Fig. 2C).


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 2.   Identification of the Top1-binding domain in nucleolin. A, silver stain of GST-nucleolin fragments purified from yeast lysates. The nucleolin residues contained in each protein are indicated. A schematic of nucleolin is included. B, GST pull-down assays using HeLa nuclear extracts and GST or the indicated GST-nucleolin fragments were performed as described in the Fig. 1 legend. Bound proteins were analyzed by SDS-PAGE followed by sequential immunoblotting using Top1 (top panel) and GST (bottom panel) antibodies. 2 µg of HeLa nuclear lysate were loaded directly onto the gel as a control. C, results of pull-down assays using additional N-terminal fragments of nucleolin. D, schematic of the results of the binding experiments, with predicted pI values of nucleolin fragments indicated.

Notably, the 125-225 nucleolin fragment has a predicted pI of 3.48, whereas the 1-125 fragment has a predicted pI of 9.45. In addition, the 224-323 fragment has a predicted pI of 3.70 and 38 sequential acidic residues (the longest uninterrupted acidic domain in the protein) and does not bind Top1. Therefore, although the acidic regions common to both the 1-125 and 125-225 nucleolin fragments may be involved in Top1-binding, global acidic charge is not sufficient to explain binding of nucleolin fragments to the relatively basic Top1 protein.

The N terminus of nucleolin is implicated in NLS binding and nucleocytoplasmic transport (39, 40). In addition, nucleolin binds an NLS-containing region in Top1 that is required for the nuclear localization of Top1 (23, 60). Taken together with our finding that the N terminus of nucleolin is sufficient for Top1 binding, these data suggest that nucleolin might function in the nucleocytoplasmic transport of Top1. While a variety of strategies might be envisioned to test this hypothesis in mammalian cells, the facility of yeast in previous studies of Top1 prompted us to investigate this question using S. cerevisiae (61).

Physical Interaction between Nsr1p and Yeast Top1p-- The S. cerevisiae protein Nsr1p is similar to nucleolin in sequence and function (51, 62-64): Nsr1p has an acidic N-terminal region with several putative phosphorylation sites, a middle region with two RBDs, and a C-terminal GAR domain. To determine whether yTop1p physically interacts with Nsr1p, we initially attempted co-immunoprecipitations using yTop1p and Nsr1p antibodies, but were not able to precipitate either protein using its respective antibody. We therefore constructed a vector expressing a GST-Nsr1p fusion protein under the control of a galactose-inducible promoter. In SDS-PAGE analyses of lysates from yeast that were induced to express GST-Nsr1p, an appropriately migrating protein was recognized by an Nsr1p antibody (data not shown). Subsequently, lysates from cells expressing GST alone or the GST-Nsr1p protein were incubated with glutathione beads, with bound proteins subjected to immunoblotting using GST and yTop1p antibodies. In cells expressing GST alone, only GST was precipitated by glutathione beads (Fig. 3C). By contrast, in cells expressing GST-Nsr1p, both this protein and yTop1 were precipitated by the beads (Fig. 3C). Taken together with the prior nucleolin-Top1 data (23), these results indicate that a physical interaction between nucleolin and Top1 orthologs is detectable in both yeast and human cells.


View larger version (10K):
[in this window]
[in a new window]
  		Fig. 3.   yTop1p co-precipitates with Nsr1p. Lanes 1 and 2, pull-down assays were performed using 20 µl of glutathione beads and 3 mg of lysate obtained from yeast expressing either GST or GST-Nsr1p (indicated at the top of each lane). Bound proteins were analyzed by SDS-PAGE and immunoblotting using yTop1p (top panel) and GST (bottom panel) antibodies. Lanes 3 and 4, 30 µg of lysate obtained from yeast expressing either GST or GST-Nsr1p were loaded directly onto the gel. Bands representing yTop1p, GST-Nsr1p, and GST are indicated by arrows.

Altered Localization of yTop1p in a Delta nsr1 Strain-- To determine whether the yTop1p-Nsr1p interaction is important in the cellular localization of yTop1p, we studied yTop1p localization in isogenic NSR1+ and Delta nsr1 strains expressing yTop1p fused to GFP. In the NSR1+ and Delta nsr1 strains, expression of the GFP protein alone was associated with diffuse cellular fluorescence (data not shown). By contrast, in the NSR1+ strain the GFP-yTop1p protein exhibited a punctate subnuclear fluorescent pattern suggestive of nucleolar localization (Fig. 4A). Similar results were obtained when GFP-yTop1p was expressed in an NSR1+Delta top1 strain, indicating that GFP-yTop1p localization is not altered by the presence of endogenous yTop1p (data not shown). In contrast to NSR1+ cells, GFP-yTop1p fluorescence was present diffusely throughout the nucleus in Delta nsr1 cells (Fig. 4A). Furthermore, in some Delta nsr1 cells the GFP-yTop1p fluorescence appeared to include an area larger than the DAPI-stained nucleus, suggestive of a perinuclear distribution (Fig. 4A, arrow). These data indicate that NSR1 is important in determining the cellular localization of a recombinant yTop1p protein.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 4.   Altered localization of GFP-yTop1p in Delta nsr1 cells. A, S. cerevisiae strains FY251 (NSR1+) and TE25 (Delta nsr1) were transformed with vectors expressing GFP-yTop1p. Two hours after induction of protein expression by addition of galactose, the cells were stained with DAPI and imaged by fluorescent and phase contrast microscopy. The arrow indicates a cell in which the GFP-yTop1p fluorescence encompasses an area larger than the DAPI-stained nucleus. B, the same strains were transformed with a vector expressing GFP-Nop1p and imaged 2 h after induction of protein expression by galactose. C, GFP-yTop1p localization in FY251 cells before and after a 25-min exposure to 100 µg/ml of the transcriptional inhibitor phenanthroline.

To determine whether the alteration in GFP-yTop1p localization was related to a general disruption in nucleolar structure, we also studied the localization of a GFP-Nop1p fusion protein in the two strains (65). In contrast to the results obtained with GFP-yTop1p, GFP-Nop1p localization was similar in NSR1+ and Delta nsr1 strains (Fig. 4B). As an additional control, we questioned whether the altered localization of yTop1p in Delta nsr1 cells was related to the transcriptional defect present in Delta nsr1 cells (51). Exposure to 100 µg/ml phenanthroline (66), which is sufficient to inhibit [3H]uridine incorporation in the NSR1+ strain by approximately 50% (data not shown), did not affect the localization of GFP-yTop1p in this strain (Fig. 4C). These findings indicate that the altered distribution of GFP-yTop1p in Delta nsr1 cells is not due to gross disruption of nucleoli or transcription.

Immunoblotting experiments were performed using whole cell, nuclear, and cytoplasmic lysates to further characterize the cellular localization of GFP-yTop1p and endogenous yTop1p in NSR1+ and Delta nsr1 cells. Levels of GFP-yTop1p in whole cell lysates were similar in the two strains, excluding overexpression of GFP-yTop1p as a cause for the more diffuse localization of this protein in the Delta nsr1 strain (Fig. 5). Expression of endogenous yTop1p was also similar in the two strains (Fig. 5). Furthermore, GFP-yTop1p and endogenous yTop1p were detectable in nuclear but not cytoplasmic lysates in both strains (Fig. 5). GFP-yTop1p was also undetectable when the cytoplasmic lysates were immunoblotted with a GFP antibody (data not shown). Coomassie staining excluded unequal loading as a cause for the lack of detection of GFP-yTop1p in the cytoplasm of Delta nsr1 cells (Fig. 5). In addition, actin was detectable in cytoplasmic but not nuclear lysates (Fig. 5). These results are consistent with those obtained using fluorescent microscopy and indicate that yTop1p remains predominantly intranuclear in Delta nsr1 cells.


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 5.   Immunoblotting analysis of the localization of yTop1p in NSR1+ and Delta nsr1 cells. Whole cell (WCL), cytoplasmic (CYTO), and nuclear lysates (NUC) were obtained from FY251 (+) and TE25 (triangle ) cells and analyzed by immunoblotting (with either yTop1p or actin antibodies) or subjected to Coomassie staining. Protein quantities were approximately 7.5, 14, and 5 µg in the whole cell, cytoplasmic, and nuclear lysate lanes, respectively. Bands representing endogenous yTop1p (asterisk) and intact and presumably degraded GFP-yTop1p (arrowheads) are indicated.

Loss of TOP1 Results in a Growth Defect in a NSR1+ but Not a Delta nsr1 Strain-- Since loss of NSR1 in yeast confers a more significant growth defect than loss of TOP1 (51, 62, 67), and our data indicate that the yTop1p and Nsr1p proteins may exist as a complex, we hypothesized that growth of a strain lacking both proteins might be similar to that of a strain lacking NSR1 alone. To test this hypothesis, strain JCW27, which lacks TOP1, and strain TE13, which lacks NSR1, were mated and tetrads from the cross were dissected. Most tetrads yielded four viable colonies, suggesting that a Delta nsr1/Delta top1 strain was viable (Fig. 6A). Indeed, immunoblotting revealed that several segregants lacked both Top1p and Nsr1p expression (Fig. 6B and data not shown). The growth rates of tetratype colonies were compared at 30 °C using nonselective media. Similar to previous studies (51, 67), we found that loss of NSR1 resulted in a 1.5-fold decrease in exponential growth rate at 30 °C, whereas loss of TOP1 resulted in a detectable but lesser growth defect (Fig. 6A and data not shown). By contrast, loss of TOP1 in the Delta nsr1 strain did not result in a further growth defect (Fig. 6A and data not shown). Thus, the growth rate of a strain lacking both TOP1 and NSR1 is similar to that of a strain lacking NSR1 alone.


View larger version (9K):
[in this window]
[in a new window]
  		Fig. 6.   Loss of TOP1 results in a growth defect in a NSR1+ but not a Delta nsr1 strain. A, tetrads resulting from a JCW27 (Delta top1 NSR1+) × TE13 (TOP1+ Delta nsr1) cross were dissected and grown at 30 °C on nonselective media for 4 days. Growth of four tetrads is shown. B, lysates obtained from segregants D1-4 were analyzed by immunoblotting with Nsr1p (top panel) and yTop1p (bottom panel) antibodies. The inferred genotype is indicated at the top of each lane.

Loss of NSR1 Results in Resistance to Camptothecin and Increased Sensitivity to m-AMSA-- We questioned whether or not the alteration of yTop1p distribution in Delta nsr1 strains was associated with a change in cellular sensitivity to the topoisomerase I-targeting drug CPT. Drug sensitivity assays were performed using strains JN284 and an isogenic Delta nsr1 derivative (TE284), which contain a drug permeability alteration that enhances cellular accumulation of CPT and other drugs (3). When serial dilutions of large numbers of cells were spotted in the absence of drug or in the presence of Me2SO alone, the growth defect conferred by loss of NSR1 was apparent (Fig. 7A). However, in the presence of 5 µg/ml CPT the growth of both strains appeared similar, with the NSR1+ strain exhibiting about a 100-fold decrease in clonogenicity under these conditions and the Delta nsr1 strain exhibiting only a 10-fold decrease in clonogenicity (Fig. 7A). By contrast, the presence of 100 µg/ml of the topoisomerase II poison m-AMSA minimally affected the growth of the NSR1+ strain, whereas this drug concentration resulted in about a 10-fold decrease in clonogenicity in the Delta nsr1 strain (Fig. 7A). The strains exhibited similar decreases in clonogenicity in the presence of 0.001% of the alkylating agent methyl methane sulfonate or 0.75 milliunits/ml of the DNA-damaging agent bleomycin (Fig. 7A). To confirm that loss of NSR1 alters cellular sensitivity to CPT and m-AMSA, we also examined the survival of a few hundred isolated cells from each strain on agar plates containing different CPT and m-AMSA concentrations. Consistent with the serial dilution assays, the results of these experiments indicated that the Delta nsr1 strain was relatively resistant to CPT but hypersensitive to m-AMSA (Fig. 7B).


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 7.   Loss of NSR1 confers resistance to camptothecin and hypersensitivity to m-AMSA. A, isogenic NSR1+ (strain JN284) and Delta nsr1 (strain TE284) colonies were grown overnight in YPD and the cultures adjusted to an A600 of 2.0. Duplicate 4-µl aliquots of serial 10-fold dilutions were then spotted onto YPD plates, which were incubated at 30 °C for 2 days. As indicated, the plates either contained no drug, 0.001% methyl methane sulfonate, 0.75 milliunit/ml bleomycin, 100 µg/ml m-AMSA, or 5 µg/ml camptothecin (in 0.125% Me2SO, 25 mM HEPES, pH 7.2). As an additional control, cells were also spotted onto a YPD plate containing 0.125% Me2SO and 25 mM HEPES, pH 7.2 (labeled +DMSO). B, equal numbers of either NSR1+ (open squares) or Delta nsr1 (closed circles) cells were incubated for 2 days at 30 °C on YPD plates containing either no drug or various concentrations of camptothecin or m-AMSA. Results are expressed as a percentage of the number of colonies present on plates lacking drug. The mean values of duplicate independent experiments are shown, with S.E. bars included.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Based upon reports that nucleolin is a helicase, we initially hypothesized that the nucleolin-Top1 complex might be analogous to other helicase-topoisomerase interactions, such as the T antigen-Top1 and Sgs1-Top3 complexes (24, 25, 68, 69). However, our purified GST-nucleolin did not exhibit helicase activity (data not shown), and others have not been able to detect helicase activity using purified mammalian nucleolin (49). As an alternate hypothesis, we considered the possibility that nucleolin functions to recruit Top1 to sites of rDNA transcription. Consistent with this model, our data indicate that the N terminus of nucleolin is necessary and sufficient for binding to Top1. Olson and Melese originally proposed that the acidic N-terminal region of nucleolin recruits proteins important in ribosome biogenesis, while the nucleolin RBDs interact with rRNA (37, 70). Recent data confirm and extend this model of nucleolin as a scaffold protein. Nucleolin binds avidly to G quartets, which are four-stranded planar structures that form in G-rich DNA in vitro and are likely to occur in the G-rich rDNA (71). The N terminus of nucleolin is dispensable for G quartet binding (71). Similarly, an in vitro assay demonstrated that the N-terminal ~300 residues of nucleolin are dispensable for rRNA binding, but required for the first step in rRNA processing, which involves cleavage of the 5' external transcribed spacer (72). Thus, nucleolin may organize an rRNA synthesis and processing complex, with the RBDs and GAR domain involved in localizing nucleolin to rDNA transcription sites and the N terminus involved in recruitment of proteins such as Top1 (49). Interestingly, like Top1 (45, 46, 73, 74), nucleolin has been implicated in transcriptional elongation (75). Therefore, it is possible that the nucleolin-Top1 interaction is particularly important in the elongation phase of rDNA transcription.

The hypothesis that nucleolin functions to recruit Top1 to sites of rDNA transcription in the nucleolus is supported by our studies of the S. cerevisiae nucleolin ortholog Nsr1p, which indicate that Nsr1p binds yTop1p and is important in determining the subnuclear localization of yTop1p. The apparent localization of a GFP-yTop1p fusion protein to the nucleolus of wild-type yeast cells is consistent with previous studies indicating that yTop1p is important in rDNA transcription, rDNA genomic stability, and rDNA silencing (44, 47, 48, 76-78). Top1 may also be important in nucleolar rRNA processing: mammalian cells treated with CPT exhibit defects in rRNA processing (41, 42) and decreased 60 S ribosomal subunits have been observed in yeast Delta top1 mutants (79). Notably, our finding that loss of TOP1 results in a growth defect in an NSR1+ but not in an isogenic Delta nsr1 strain supports a predominant role for yTop1p in the nucleolus.

Results obtained with the Delta nsr1 strain also indicate that cellular sensitivity to CPT may be modulated by proteins that bind Top1. Although previous work indicated that helicase-Top1 interactions may inhibit CPT-mediated cleavable complex formation (14), to our knowledge our studies are the first to demonstrate that loss of a Top1-binding protein may change cellular sensitivity to CPT. Since the localization of yTop1p is altered in the Delta nsr1 strain, it is tempting to speculate that this altered localization is responsible for the resistant phenotype. An intriguing possibility is that cleavable complex formation after CPT exposure is reduced in the Delta nsr1 strain as a result of mislocalized yTop1p. A plausible alternative model is that cleavable complex formation after CPT exposure is maintained in the Delta nsr1 strain, but that conversion of these complexes to lethal DNA damage is reduced as a result of altered localization of yTop1p. Notably, a defect in topoisomerase I function in the Delta nsr1 strain may also explain the hypersensitivity to m-AMSA exhibited by this strain, since increased sensitivity to topoisomerase II-targeting drugs is also found in strains in which TOP1 is disrupted, presumably resulting from a compensatory activity of Top2p (4).

While we cannot exclude the possibility that the slower growth rate of the Delta nsr1 strain may result in decreased conversion of CPT-induced yTop1p cleavable complexes to lethal DNA damage, this possibility seems unlikely for the following reasons: 1) the Delta nsr1 strain is not resistant to a topoisomerase II-targeting drug or other DNA-damaging agents, and 2) previous studies found no correlation between cellular doubling times and sensitivity to CPT (9, 80). Further studies of Delta nsr1 strains are necessary to determine the mechanisms of CPT resistance and m-AMSA hypersensitivity conferred by loss of NSR1. Notably, drug resistance associated with altered localization of a topoisomerase has been described for several mammalian cell lines that are resistant to Top2-targeting drugs, in which the cellular localization of Top2alpha is cytoplasmic rather than nuclear as a result of mutations in the Top2alpha NLS (81-84).

Our results are also relevant to the altered localization of Top1 that occurs after cellular exposure to CPT. Recent experiments using a GFP-tagged N-terminal region of Top1 indicate that after treatment with CPT, the localization of this fusion protein changes from a nucleolar to a diffusely nuclear pattern (85). Moreover, a change in nucleolin localization from the nucleolus to the nucleus or even cytoplasm was observed after cellular exposure to mitomycin C, heat shock, or actinomycin D (86, 87). The N terminus of Top1 contains the nucleolin-binding site but is catalytically inactive and does not interact with CPT (23). Thus, it is possible that either a change in nucleolin localization or in the interaction between nucleolin and the N terminus of Top1 is involved in the altered localization of Top1 that occurs after CPT exposure.

    ACKNOWLEDGEMENTS

We thank the following individuals: Mary-Ann Bjornsti for helpful discussions as well as ScTOP1 vectors and yTop1p antibodies, John Nitiss for strain JN284, Masayori Inouye for plasmids pICS16 and pYCB5, John Woolford for the Nsr1p antibody, Y. C. Cheng for the human Top1 antibody, W. Steven Ward for assistance with fluorescence microscopy, Nancy C. Walworth for assistance with tetrad dissections, and Y. Lin and W. J. Shih for statistical analyses.

    FOOTNOTES

* This work was supported by United States Public Health Service Grants CA70981 and GM59170 (to E. H. R.) and GM51402 (to M. R. G.), awarded by the National Cancer Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to this work.

§ To whom correspondence should be addressed. Tel.: 723-235-7955; Fax: 723-235-7493; E-mail: ehrubin@umdnj.edu.

Published, JBC Papers in Press, August 30, 2000, DOI 10.1074/jbc.M006628200

2 M. Snyder and C. Copeland, unpublished data.

    ABBREVIATIONS

The abbreviations used are: Top1, topoisomerase I; CPT, camptothecin; RBD, RNA-binding domain; GAR, glycine-arginine-rich; NLS, nuclear localization sequence; PCR, polymerase chain reaction; GST, glutathione S-transferase; GFP, green fluorescent protein; PAGE, polyacrylamide gel electrophoresis; m-AMSA, amsacrine; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; DAPI, 4',6-diamidino- 2-phenylindole.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Chen, A. Y., and Liu, L. F. (1994) Annu. Rev. Pharmacol. Toxicol. 34, 191-218
2. Wang, J. C. (1996) Annu. Rev. Biochem. 65, 635-692
3. Nitiss, J., and Wang, J. C. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7501-7505
4. Eng, W. K., Faucette, L., Johnson, R. K., and Sternglanz, R. (1988) Mol. Pharmacol. 34, 755-760
5. Bjornsti, M., Benedetti, P., Vigilanti, G., and Wang, J. (1989) Cancer Res. 49, 6318-6323
6. Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., and Hol, W. G. J. (1998) Science 279, 1504-1513
7. Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G. J., and Champoux, J. J. (1998) Science 279, 1534-1541
8. Fan, Y., Weinstein, J. N., Kohn, K. W., Shi, L. M., and Pommier, Y. (1998) J. Med. Chem. 41, 2216-2226
9. Goldwasser, F., Bae, I., Valenti, M., Torres, K., and Pommier, Y. (1995) Cancer Res. 55, 2116-2121
10. Beidler, D. R., Chang, J. Y., Zhou, B. S., and Cheng, Y. C. (1996) Cancer Res. 56, 345-353
11. Sorensen, M., Sehested, M., Christensen, I. J., Larsen, J. K., and Jensen, P. B. (1998) Br. J. Cancer 77, 2152-2161
12. Hsiang, Y., Lihou, M., and Liu, L. (1989) Cancer Res. 49, 5077-5082
13. Wu, J., and Liu, L. F. (1997) Nucleic Acids Res. 25, 4181-4186
14. Pommier, Y., Kohlhagen, G., Wu, C., and Simmons, D. T. (1998) Biochemistry 37, 3818-3823
15. Beidler, D. R., and Cheng, Y. (1995) Mol. Pharmacol. 47, 907-914
16. Desai, S. D., Liu, L. F., Vazquez-Abad, D., and D'Arpa, P. (1997) J. Biol. Chem. 272, 24159-24164
17. Danks, M. K., Garrett, K. E., Marion, R. C., and Whipple, D. O. (1996) Cancer Res. 56, 1664-1673
18. Buckwalter, C. A., Lin, A. H., Tanizawa, A., Pommier, Y. G., Cheng, Y.-C., and Kaufmann, S. H. (1996) Cancer Res. 56, 1674-1681
19. Wadkins, R. M., Danks, M. K., Horowitz, L., and Baker, S. D. (1998) Exp Cell Res 241, 332-339
20. Javaherian, K., and Liu, L. F. (1983) Nucleic Acids Res. 11, 461-472
21. Kordiyak, G. J., Jakes, S., Ingebritsen, T. S., and Benbow, R. M. (1994) Biochemistry 33, 13484-13491
22. Rose, K. M., Szopa, J., Han, F., Cheng, Y.-C., Richter, A., and Scheer, U. (1988) Chromosoma (Berl.) 96, 411-416
23. Bharti, A. K., Olson, M. O. J., Kufe, D. W., and Rubin, E. H. (1996) J. Biol. Chem. 271, 1993-1997
24. Simmons, D. T., Melendy, T., Usher, D., and Stillman, B. (1996) Virology 222, 365-374
25. Haluska, P., Saleem, A., Edwards, T. K., and Rubin, E. H. (1998) Nucleic Acids Res. 26, 1841-1847
26. Gobert, C., Bracco, L., Rossi, F., Olivier, M., Tazi, J., Lavelle, F., Larsen, A. K., and Riou, J. F. (1996) Biochemistry 35, 5778-5786
27. Albor, A., Kaku, S., and Kulesz-Martin, M. (1998) Cancer Res. 58, 2091-2094
28. Merino, A., Madden, K. R., Lane, W. S., Champoux, J. J., and Reinberg, D. (1993) Nature 365, 227-232
29. Rossi, F., Labourier, E., Forne, T., Divita, G., Derancourt, J., Riou, J. F., Antoine, E., Cathala, G., Brunel, C., and Tazi, J. (1996) Nature 381, 80-82
30. Straub, T., Grue, P., Uhse, A., Lisby, M., Knudsen, B. R., Tange, T., Westergaard, O., and Boege, F. (1998) J. Biol. Chem. 273, 26261-26264
31. Haluska, P. H., Saleem, A., Rasheed, Z., Ahmed, F., Su, E. W., Liu, L. F., and Rubin, E. H. (1999) Nucleic Acids Res. 27, 2538-2544
32. Park, H., and Sternglanz, R. (1999) Yeast 15, 35-41
33. Straight, A. F., Shou, W., Dowd, G. J., Turck, C. W., Deshaies, R. J., Johnson, A. D., and Moazed, D. (1999) Cell 97, 245-256
34. Shou, W., Seol, J. H., Shevchenko, A., Baskerville, C., Moazed, D., Chen, Z. W., Jang, J., Charbonneau, H., and Deshaies, R. J. (1999) Cell 97, 233-244
35. Duguet, M. (1997) J. Cell Sci. 110, 1345-1350
36. Bugler, B., Bourbon, H., Lapeyre, B., Wallace, M. O., Chang, J. H., Amalric, F., and Olson, M. O. (1987) J. Biol. Chem. 262, 10922-10925
37. Sapp, M., Richter, A., Weisshart, K., Caizergues-Ferrer, M., Amalric, F., Wallace, M. O., Kirstein, M. N., and Olson, M. O. J. (1989) Eur. J. Biochem. 179, 541-548
38. Tuteja, N., Huang, N. W., Skopac, D., Tuteja, R., Hrvatic, S., Zhang, J., Pongor, S., Joseph, G., Faucher, C., Amalric, F., and Falashi, A. (1995) Gene (Amst.) 160, 143-148
39. Borer, R. A., Lehner, C. F., Eppenberger, H. M., and Nigg, E. A. (1989) Cell 56, 379-390
40. Xue, Z., Shan, X., Lapeyre, B., and Melese, T. (1993) Eur. J. Cell Biol. 62, 13-21
41. Wu, R. S., Kumar, A., and Warner, J. R. (1971) Proc. Natl. Acad. Sci., U. S. A. 12, 3009-3014
42. Abelson, H. T., and Penman, S. (1972) Nat. New Biol. 237, 144-146
43. Bonven, B. J., Gocke, E., and Westergaard, O. (1985) Cell 41, 541-551
44. Brill, S. J., DiNardo, S., Voelkel-Meiman, K., and Sternglanz, R. (1987) Nature 326, 414-416
45. Egyhazi, E., and Durban, E. (1987) Mol. Cell. Biol. 7, 4308-4316
46. Zhang, H., Wang, J. C., and Liu, L. F. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 1060-1064
47. Schultz, M. C., Brill, S. J., Ju, Q., Sternglanz, R., and Reeder, R. H. (1992) Genes Dev. 6, 1332-1341
48. Gadal, O., Mariotte-Labarre, S., Chedin, S., Quemeneur, E., Carles, C., Sentenac, A., and Thuriaux, P. (1997) Mol. Cell. Biol. 17, 1787-1795
49. Ginisty, H., Sicard, H., Roger, B., and Bouvet, P. (1999) J. Cell Sci. 112, 761-772
50. Tsalik, E. L., and Gartenberg, M. R. (1998) Yeast 14, 847-852
51. Kondo, K., and Inouye, M. (1992) J. Biol. Chem. 267, 16252-16258
52. Winston, F., Dollard, C., and Ricupero-Hovasse, S. L. (1995) Yeast 11, 53-55
53. Mirabella, A., and Gartenberg, M. R. (1997) EMBO J. 16, 523-533
54. Mitchell, D. A., Marshall, T. K., and Deschenes, R. J. (1993) Yeast 9, 715-722
55. Cheng, T. H., Li, Y. C., and Gartenberg, M. R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5521-5526
56. Fang, S., and Yeh, N. (1993) Exp. Cell Res. 208, 48-53
57. Chang, J., Dethlefsen, L. A., Barley, L. R., Zhou, B., and Cheng, Y. (1992) Biochem. Pharmacol. 43, 2443-2452
58. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B., and Kufe, D. (1994) J. Biol. Chem. 269, 2433-2439
59. Reid, R. J. D., Kauh, E. A., and Bjornsti, M.-A. (1997) J. Biol. Chem. 272, 12091-12099
60. Alsner, J., Svejstrup, J. Q., Kjeldsen, E., Sorenson, B. S., and Westergaard, O. (1992) J. Biol. Chem. 267, 12408-12411
61. Reid, R. J., Benedetti, P., and Bjornsti, M. A. (1998) Biochim. Biophys. Acta 1400, 289-300
62. Lee, W., Xue, Z., and Melese, T. (1991) J. Cell Biol. 113, 1-12
63. Kondo, K., Kowalski, L. R. Z., and Inouye, M. (1992) J. Biol. Chem. 267, 16259-16265
64. Lee, W. C., Zabetakis, D., and Melese, T. (1992) Mol. Cell. Biol. 12, 3865-3871
65. Henriquez, R., Blobel, G., and Aris, J. P. (1990) J. Biol. Chem. 265, 2209-2215
66. Santiago, T. C., Purvis, I. J., Bettany, A. J., and Brown, A. J. (1986) Nucleic Acids Res. 14, 8347-8360
67. Thrash, C., Bankier, A. T., Barrell, B. G., and Sternglanz, R. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 4374-4378
68. Gangloff, S., McDonald, J. P., Bendixen, C., Arthur, L., and Rothstein, R. (1994) Mol. Cell. Biol. 14, 8391-8398
69. Watt, P. M., Louis, E. J., Borts, R. H., and Hickson, I. D. (1995) Cell 81, 253-260
70. Xue, Z., and Melese, T. (1994) Trends Cell Biol. 4, 414-417
71. Hanakahi, L. A., Sun, H., and Maizels, N. (1999) J. Biol. Chem. 274, 15908-15912
72. Ginisty, H., Amalric, F., and Bouvet, P. (1998) EMBO J. 17, 1476-1486
73. Bendixen, C., Thomsen, B., Alsner, J., and Westergaard, O. (1990) Biochemistry 29, 5613-5619
74. Gartenberg, M. R., and Wang, J. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11461-11465
75. Bouche, G., Caizergues-Ferrer, M., Bugler, B., and Amalric, F. (1984) Nucleic Acids Res. 12, 3025-3035
76. Bryk, M., Banerjee, M., Murphy, M., Knudsen, K. E., Garfinkel, D. J., and Curcio, M. J. (1997) Genes Dev. 11, 255-269
77. Christman, M. F., Dietrich, F. S., and Fink, C. R. (1988) Cell 55, 413-425
78. Kim, R. A., and Wang, J. C. (1989) Cell 57, 975-985
79. Ohtake, Y., and Wickner, R. B. (1995) Mol. Cell. Biol. 15, 2772-2781
80. Pantazis, P., Dejesus, A., Early, J., Rodriguez, R., Chatterjee, D., Han, Z., Wyche, J., and Giovanella, B. (1995) Anticancer Res. 15, 1873-1881
81. Feldhoff, P. W., Mirski, S. E., Cole, S. P., and Sullivan, D. M. (1994) Cancer Res. 54, 756-762
82. Mirski, S. E. L., and Cole, S. P. C. (1995) Cancer Res. 55, 2129-2134
83. Harker, W. G., Slade, D. L., Parr, R. L., and Holguin, M. H. (1995) Cancer Res. 55, 4962-4971
84. Wessel, I., Jensen, P. B., Falck, J., Mirski, S. E., Cole, S. P., and Sehested, M. (1997) Cancer Res. 57, 4451-4454
85. Mo, Y. Y., Wang, P., and Beck, W. T. (2000) Exp. Cell Res. 256, 480-490
86. Daniely, Y., and Borowiec, J. A. (2000) J. Cell Biol. 149, 799-810
87. David-Pfeuty, T. (1999) Oncogene 18, 7409-7422

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 GeneticsHome page
M. P. Andersen, Z. W. Nelson, E. D. Hetrick, and D. E. Gottschling
A Genetic Screen for Increased Loss of Heterozygosity in Saccharomyces cerevisiae
Genetics, July 1, 2008; 179(3): 1179 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z.-H. Miao, A. Player, U. Shankavaram, Y.-H. Wang, D. B. Zimonjic, P. L. Lorenzi, Z.-Y. Liao, H. Liu, T. Shimura, H.-L. Zhang, et al.
Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses
Cancer Res., September 15, 2007; 67(18): 8752 - 8761.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. C. Girvan, Y. Teng, L. K. Casson, S. D. Thomas, S. Juliger, M. W. Ball, J. B. Klein, W. M. Pierce Jr., S. S. Barve, and P. J. Bates
AGRO100 inhibits activation of nuclear factor-{kappa}B (NF-{kappa}B) by forming a complex with NF-{kappa}B essential modulator (NEMO) and nucleolin.
Mol. Cancer Ther., July 1, 2006; 5(7): 1790 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Yu, E. Khan, M. A. Khaleque, J. Lee, G. Laco, G. Kohlhagen, S. Kharbanda, Y.-C. Cheng, Y. Pommier, and A. Bharti
Phosphorylation of DNA Topoisomerase I by the c-Abl Tyrosine Kinase Confers Camptothecin Sensitivity
J. Biol. Chem., December 10, 2004; 279(50): 51851 - 51861.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Rajendra, D. Malegaonkar, P. Pungaliya, H. Marshall, Z. Rasheed, J. Brownell, L. F. Liu, S. Lutzker, A. Saleem, and E. H. Rubin
Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53
J. Biol. Chem., August 27, 2004; 279(35): 36440 - 36444.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. O. Christensen, H. U. Barthelmes, F. Boege, and C. Mielke
Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro
Nucleic Acids Res., December 15, 2003; 31(24): 7255 - 7263.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Rallabhandi, K. Hashimoto, Y.-Y. Mo, W. T. Beck, P. K. Moitra, and P. D'Arpa
Sumoylation of Topoisomerase I Is Involved in Its Partitioning between Nucleoli and Nucleoplasm and Its Clearing from Nucleoli in Response to Camptothecin
J. Biol. Chem., October 11, 2002; 277(42): 40020 - 40026.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Shibata, T. Muramatsu, M. Hirai, T. Inui, T. Kimura, H. Saito, L. M. McCormick, G. Bu, and K. Kadomatsu
Nuclear Targeting by the Growth Factor Midkine
Mol. Cell. Biol., October 1, 2002; 22(19): 6788 - 6796.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. O. Christensen, H. U. Barthelmes, F. Boege, and C. Mielke
The N-terminal Domain Anchors Human Topoisomerase I at Fibrillar Centers of Nucleoli and Nucleolar Organizer Regions of Mitotic Chromosomes
J. Biol. Chem., September 20, 2002; 277(39): 35932 - 35938.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Marchand, P. Pourquier, G. S. Laco, N. Jing, and Y. Pommier
Interaction of Human Nuclear Topoisomerase I with Guanosine Quartet-forming and Guanosine-rich Single-stranded DNA and RNA Oligonucleotides
J. Biol. Chem., March 8, 2002; 277(11): 8906 - 8911.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. H. Woo, J. R. Vance, A. R. O. Marcos, C. Bailly, and M.-A. Bjornsti
Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin
J. Biol. Chem., February 1, 2002; 277(6): 3813 - 3822.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/46/36181    most recent
M006628200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edwards, T. K.
Right arrow Articles by Rubin, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edwards, T. K.
Right arrow Articles by Rubin, E. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement